SOURCE: Smallcap-Investors

November 05, 2009 08:18 ET

Stocks on the Move: TPIV, INO, MBCI, CRXL

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by

BOCA RATON, FL--(Marketwire - November 5, 2009) - TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V (NASDAQ: CRXL).

Terms of the agreement allow TapImmune to use the proprietary PER.C6® cells in its development programs. The PER.C6® cell line is suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6® cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.

Inovio Biomedical Corporation (AMEX: INO) engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines rose almost 4% for the week.

Yesterday, MabCure N.V, a subsidiary of MabCure Inc. (OTCBB: MBCI), announced the signing of a research agreement with AZ Sint Lucas Hospital, Brugge, Belgium, to conduct preclinical research on its Monoclonal Antibodies (Mabs) against different cancers.

About is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. Smallcap-Investors goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. offers a free financial newsletter. To subscribe or get more information, visit our home page located at An affiliate of has been promised compensation by TapImmune Inc. for the dissemination of this Press Release.

Contact Information